46 completed, 19 terminated, 6 active not recruiting, 5 unknown. 86 Phase 1, 23 Phase 2.
Follow Refractory Chronic Lymphocytic Leukemia: new trials by email Literature Review of Refractory Chronic Lymphocytic Leukemia trials Research Report on Refractory Chronic Lymphocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL Roginolisib, Obinutuzumab, Venetoclax - Chronic Lymphocytic Leukemia (CLL), Refractory Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 40 | 2027-01-13 | 2026-09-29 |
| Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia Autologous Anti-CD19/CD20/CD22 CAR T-cells, Biospecimen Collection, Bone Marrow Aspiration - Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia | Phase 1 | Active not recruiting | Ohio State University Comprehensive Cancer Center | 24 | 2026-01-14 | 2026-08-26 |
| Q702 for the Treatment of Patients With Hematologic Malignancies Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration - Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma | Phase 1 | Recruiting | Mayo Clinic | 46 | 2025-08-27 | 2025-10-10 |
| Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Terminated | Roswell Park Cancer Institute | 1 | 2024-11-26 | 2025-08-03 |
| B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies Autologous BAFFR-targeting CAR T Cells, Bendamustine, Biopsy - B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Recruiting | Mayo Clinic | 27 | 2024-03-18 | 2026-02-13 |
| A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies BGB-21447 - Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | Phase 1 | Terminated | BeOne Medicines | 51 | 2023-06-20 | 2026-07-14 |
| CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563, Bendamustine, Biospecimen Collection - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Recruiting | Mayo Clinic | 25 | 2022-10-03 | 2026-06-09 |
| Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation Ibrutinib, Ipilimumab, Nivolumab - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2022-07-14 | 2025-02-28 | |
| Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies Anti-CD19/CD20/CD22 CAR T-Cells, Cyclophosphamide, Fludarabine Phosphate - Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | Sumithira Vasu | 54 | 2022-06-30 | 2026-05-29 |
| A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome VIP152, BTKi - Relapsed Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Terminated | Vincerx Pharma, Inc. | 6 | 2021-12-16 | 2023-11-18 |
| CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma Lenalidomide, Obinutuzumab, Oral Azacitidine - Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | Joseph Tuscano | 8 | 2020-10-23 | 2025-04-24 |
| Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL Dose combination 1-1, dose combination 1-2, Dose combination 1-3 - Chronic Lymphocytic Leukemia, CLL | Phase 1 | Withdrawn | Virginia Commonwealth University | 2020-10-02 | 2021-11-09 | |
| CD19-Specific T Cells Post AlloSCT Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells, Cyclophosphamide, Fludarabine - B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Terminated | M.D. Anderson Cancer Center | 4 | 2020-06-26 | 2021-06-02 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate - CD19 Positive, CD20 Positive | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 24 | 2019-10-04 | 2026-08-20 |
| Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor Trabectedin, Venetoclax - Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2019-06-18 | 2023-09-25 | |
| Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma Autologous CD19/CD22 Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine - CD19 Positive, CD22 Positive | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2019-05-15 | 2023-08-21 | |
| Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma Ibrutinib, Laboratory Biomarker Analysis, Pevonedistat - B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 18 | 2018-04-27 | 2026-04-27 |
| A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Laboratory Biomarker Analysis - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 53 | 2017-12-05 | 2026-06-22 |
| Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia Laboratory Biomarker Analysis, Metformin Hydrochloride, Pharmacological Study - Anemia, Fatigue | Phase 1 | Completed | City of Hope Medical Center | 3 | 2017-09-07 | 2026-10-19 |
Showing 20 of 86. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (86) · Lymphoma, Mantle-Cell (43) · Lymphoma, Follicular (39) · Lymphoma, Large B-Cell, Diffuse (38) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (36) · Lymphoma, B-Cell, Marginal Zone (30) · Lymphoma, Non-Hodgkin (30) · Burkitt Lymphoma (25) · Waldenstrom Macroglobulinemia (24) · Hodgkin Disease (20) · Leukemia, Prolymphocytic (20) · Lymphoma, T-Cell, Cutaneous (18) · Multiple Myeloma (18) · Mycosis Fungoides (18) · Sezary Syndrome (18)
Chronic Disease (86) · Disease Attributes (86) · Hematologic Diseases (86) · Hemic and Lymphatic Diseases (86) · Immune System Diseases (86) · Immunoproliferative Disorders (86) · Leukemia, B-Cell (86) · Lymphatic Diseases (86) · Lymphoproliferative Disorders (86) · Neoplasms by Histologic Type (86) · Pathologic Processes (86) · Pathological Conditions, Signs and Symptoms (86) · Leukemia, Lymphoid (85) · Neoplasms (85) · Leukemia (84)
Cyclophosphamide (17) · fludarabine phosphate (15) · Rituximab (13) · Biopsy (8) · Specimen Handling (8) · ibrutinib (8) · Bendamustine Hydrochloride (7) · Mycophenolic Acid (7) · fludarabine (7) · Lenalidomide (6) · Magnetic Resonance Spectroscopy (6) · Whole-Body Irradiation (6) · Cyclosporine (5) · Bortezomib (4) · Leukapheresis (4)
National Cancer Institute (NCI) (33) · Fred Hutchinson Cancer Center (11) · M.D. Anderson Cancer Center (5) · Mayo Clinic (5) · Chinese PLA General Hospital (3) · City of Hope Medical Center (3) · Case Comprehensive Cancer Center (2) · Ohio State University Comprehensive Cancer Center (2) · Roswell Park Cancer Institute (2) · Alexey Danilov, MD (1) · Amir Mortazavi (1) · BeOne Medicines (1) · Dana-Farber Cancer Institute (1) · Emory University (1) · First Affiliated Hospital of Wenzhou Medical University (1)
United States (78) · China (6) · Canada (3) · Germany (3) · Italy (3) · Australia (1) · New Zealand (1) · Poland (1)
Brenda Sandmaier (3) · David Maloney (3) · John Byrd (3) · Kristie Blum (3) · Brenda Cooper (2) · Jennifer Woyach, MD (2) · Kerry Rogers, MD (2) · Maryam Fouladi (2) · Paolo Caimi, MD (2) · Shaji Kumar (2) · Sumithira Vasu, MD (2) · Ajay Gopal (1) · Alexey Danilov (1) · Amir Mortazavi, MD (1) · Asher Chanan-Khan (1)
PMID 34515338, PMID 32499241, PMID 39863139, PMID 17679729, PMID 18974373, PMID 19679883, PMID 19826119, PMID 21072184, PMID 22259028, PMID 22289993, PMID 22308288, PMID 23256542, PMID 23393050, PMID 23887852, PMID 24474568, PMID 24990615, PMID 25317870, PMID 25444722, PMID 26853648, PMID 26943915, PMID 27111235, PMID 28270022, PMID 28314788, PMID 29038338, PMID 29263894, PMID 29572391, PMID 30111609, PMID 30562587, PMID 30728140, PMID 30729531, PMID 30782611, PMID 31076448, PMID 31617432, PMID 31648294, PMID 31815579, PMID 32245502, PMID 32795224, PMID 32967009, PMID 33357452, PMID 33492438, PMID 34196037, PMID 34608724, PMID 34666344, PMID 34935483, PMID 36631449, PMID 36873868, PMID 37774014, PMID 37882668, PMID 39333103, PMID 41804087
U01CA076576 (11), P30CA016058 (7), P30CA015704 (6), P30CA016672 (3), U01CA062502 (3), U01CA062505 (3), U01CA097452 (3), P01CA018029 (2), P01CA078902 (2), P50CA140158 (2), R01CA136551 (2), U01CA069912 (2), U01CA121947 (2), UM1CA186712 (2), UM1CA186717 (2)